West Pharmaceutical Services earnings release, July 23, 2026

West Pharmaceutical Services Inc (WST) · Form 8-K, Item 2.02 · Filed · SEC filing

West Reports Second-Quarter 2026 Results

Raising Full-Year Net Sales and EPS guidance

Exton, PA, July 23, 2026 – West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the second quarter of 2026.

Second-Quarter Summary (comparisons to prior-year period)

• Net sales of $872.3 million increased 13.8%; organic growth was 12.7%.

• Diluted earnings per share ("EPS") of $2.15 increased 18.1%.

• Adjusted-diluted EPS of $2.37 increased 28.8%.

• Operating cash flow was $213.9 million. Capital expenditures were $85.9 million. Free cash flow (defined as operating cash flow less capital expenditures) was $128.0 million.

• During the first six months of 2026, the Company repurchased 1.8 million shares for $454.3 million at an average price of $258.03 per share under its share repurchase program that was announced in mid-February 2026.

• The Company also announced on July 21, 2026 that its Board of Directors declared a third-quarter 2026 dividend of $0.22 per share.

Outlook for Full-Year and Third-Quarter 2026

• Full-year 2026 net sales are expected to be in the range of $3.345 billion to $3.380 billion, up 8.8% to 10.0% reported and up 10.0% to 11.0% organic.

• Full-year 2026 adjusted-diluted EPS guidance increased to a range of $8.85 to $9.05.

• Third-quarter 2026 net sales are expected to be in the range of $820 million to $835 million, up 1.9% to 3.8% reported and up 7.0% to 8.9% organic.

• Third-quarter 2026 adjusted-diluted EPS guidance is expected to be in the range of $2.14 to $2.24.

Eric M. Green, President, Chief Executive Officer and Chair of the Board, commented: “I am pleased to report strong second-quarter results, with net sales and adjusted EPS exceeding our expectations. Net sales increased

12.7% organically, driven by our High Value Product Components business which benefited from continued strength in Biologics, a favorable mix shift from HVP upgrades including Annex 1, and ongoing growth in GLP-1 elastomers. The robust sales growth drove strong operating income margin expansion as compared to prior year. As a result of our team's strong execution in the second quarter and improved outlook, we are increasing our full-year 2026 guidance.”

Proprietary Products Segment

Net sales of $722.6 million grew by 16.6% and increased 15.5% on an organic basis.

• High-Value Product ("HVP") Components net sales of $424.1 million increased 19.4% and rose 18.4% on an organic basis. HVP Components accounted for 49% of total company net sales in the quarter.

• HVP Delivery Devices net sales of $131.2 million increased by 29.6%, and were up 29.2% on an organic basis. HVP Delivery Devices accounted for 15% of total company net sales in the quarter.

• Standard Products net sales of $167.3 million increased by 2.4% and rose 0.7% on an organic basis. Standard Products accounted for 19% of total company net sales this quarter.

West Vantage Segment

Net sales of $149.7 million increased by 2.0% and rose 0.8% on an organic basis. West Vantage accounted for 17% of total company net sales in the quarter.

Full-Year 2026 Financial Guidance

• The Company is increasing its full-year 2026 net sales guidance range to $3.345 billion to $3.380 billion, up from $3.295 billion to $3.350 billion.

◦ Reported net sales growth is anticipated to be in the range of 8.8% to 10.0%, and organic net sales growth is expected to be in the range of 10.0% to 11.0%.

◦ Net sales guidance includes an estimated full-year 2026 benefit of approximately 1 percentage point based on current foreign currency exchange rates.

◦ SmartDose® 3.5mL generated $55 million in net sales in the second half of 2025. These net sales are excluded going forward to calculate our organic net sales growth guidance.

• The Company is increasing its full-year 2026 adjusted-diluted EPS guidance range to $8.85 to

$9.05, up from the previous range of $8.40 to $8.75.

• Capital spending guidance is unchanged from a range of $250 million to $275 million.

Third-Quarter 2026 Financial Guidance

• The Company is introducing its third-quarter 2026 net sales guidance range of $820 million to $835 million.

◦ Reported net sales growth is anticipated to be in the range of 1.9% to 3.8%, and organic net sales growth is expected to be in the range of 7.0% to 8.9%.

◦ Net sales guidance includes an estimated headwind of approximately 1 percentage point based on current foreign currency exchange rates.

◦ SmartDose® 3.5mL generated $30 million in net sales in the third quarter of 2025. These net sales are excluded going forward to calculate our organic net sales growth guidance.

• The Company is introducing its third-quarter 2026 adjusted-diluted EPS guidance range of $2.14 to $2.24.

Second-Quarter 2026 Conference Call

Management will host a conference call at 8 a.m. EDT today. The live webcast can be accessed in the "Investors" section of the Company's website at https://investor.westpharma.com/.

To participate in the Q&A portion of the conference call, please register in advance at https://edge.media-server.com/mmc/p/g76vb8x6/.

Registered telephone participants will receive the dial-in number along with a unique PIN number that will enable them to ask questions on the call.

An accompanying slide presentation will be posted in the "Investors" section of the Company's website.

A replay of the webcast will be available on the Company's website for approximately 90 days after the event.

About West... (truncated) 41 billion components and devices each year. Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included in the Standard & Poor's 500 index. For more information, visit www.westpharma.com.

All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.

Daikyo®, Daikyo Crystal Zenith® and Daikyo CZ® are registered trademarks of Daikyo Seiko, Ltd. Daikyo Crystal Zenith technologies are licensed from Daikyo Seiko, Ltd.

Financial statements

Income Statement

Three Months Ended June 30, — in millions, except per share data)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025Six Months Ended June 30, – 2025
Net sales872.3100.0%766.5100.0%1,717.2100.0%1,464.5100.0%
Cost of goods and services sold543.162492.6641,091.664958.765
Gross profit329.238273.936625.636505.835
Research and development19.7219.1235.5235.42
Selling, general and administrative expenses117.61495.913217.112183.913
Other expense (income), net12.815.2116.8125.82
Operating profit179.121153.720356.221260.718
Interest (income) expense, net-1.2-3.5-4.4-7.2
Other nonoperating expense (income)0.20.20.40.4
Income before income taxes and equity in net income of affiliated companies180.12115720360.221267.518
Income tax expense32.2430.2476.9454.34
Equity in net income of affiliated companies-6.1-1-5-1-9.5-8.4-1
Net income15418.0%131.817.0%292.817.0%221.615.0%
Net income per share:Basic2.171.824.13.06
Net income per share:Diluted2.151.824.073.05
Net income per share:Average common shares outstanding70.872.271.472.3
Net income per share:Average shares assuming dilution71.372.571.972.8

Income Statement

Three Months Ended June 30, — (in millions)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Proprietary Products722.6619.81,416.91,182.8
West Vantage149.7146.7300.3281.7
Consolidated Total872.3766.51,717.21,464.5
Gross Profit:Proprietary Products308248.3581.1458.5
Gross Profit:West Vantage21.225.644.547.3
Gross Profit:Gross Profit329.2273.9625.6505.8
Gross Profit:Gross Profit Margin37.735.736.434.5
Operating Profit (Loss):Proprietary Products211.9161.7401.1292.3
Operating Profit (Loss):West Vantage12.917.828.531.3
Operating Profit (Loss):Stock-based compensation expense-10.9-7.4-17.5-8.7
Operating Profit (Loss):General corporate costs-34.8-18.4-55.9-54.2
Operating Profit (Loss):Reported Operating Profit179.1153.7356.2260.7
Operating Profit (Loss):Reported Operating Profit Margin20.520.120.717.8
Operating Profit (Loss):Unallocated items18.31.622.219.6
Operating Profit (Loss):Adjusted Operating Profit197.4155.3378.4280.3
Operating Profit (Loss):Adjusted Operating Profit Margin22.620.32219.1

Balance Sheet

June 30, 2026 — CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (in millions, except per share data)

June 30, 2026December 31, 2025
Cash and cash equivalents435.8791.3
Accounts receivable, net712574.4
Inventories447.4443.9
Other current assets212.3168.6
Total current assets1,807.51,978.2
Property, plant and equipment3,248.63,223.4
Less: accumulated depreciation and amortization1,562.31,497
Property, plant and equipment, net1,686.31,726.4
Operating lease right-of-use assets104.7117
Investments in affiliated companies207.7212.3
Goodwill108.7109.9
Intangible assets, net6.47.7
Deferred income taxes72.338.4
Other noncurrent assets82.880.1
Total Assets4,076.44,270
Current liabilities:Accounts payable252.7253.7
Current liabilities:Accrued salaries, wages and benefits97.1135.9
Current liabilities:Income taxes payable64.728.1
Current liabilities:Operating lease liabilities20.922.7
Current liabilities:Accrued commissions, rebates and royalties3439.2
Current liabilities:Other current liabilities171.1175.3
Current liabilities:Total current liabilities640.5654.9
Current liabilities:Long-term debt202.9202.8
Current liabilities:Deferred income taxes22.423
Current liabilities:Pension and other postretirement benefits28.329
Current liabilities:Operating lease liabilities88.395.6
Current liabilities:Deferred compensation benefits13.913.5
Current liabilities:Other long-term liabilities89.975.2
Current liabilities:Total Liabilities1,086.21,094
Equity:Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: June 30, 2026 - 75.3 million, December 31, 2025 - 75.3 million; shares outstanding: June 30, 2026 - 70.4 million, December 31, 2025 - 72.0 million18.818.8
Equity:Retained earnings4,624.14,374.9
Equity:Accumulated other comprehensive loss-140.4-105.5
Equity:Treasury stock, at cost (June 30, 2026 - 4.9 million shares, December 31, 2025 - 3.3 million shares)-1,512.3-1,112.2
Equity:Total Equity2,990.23,176
Equity:Total Liabilities and Equity4,076.44,270

Cash Flow

Six Months Ended June 30, — (in millions)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Cash flows from operating activities:Net income292.8221.6
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation90.379.9
Adjustments to reconcile net income to net cash provided by operating activities:Amortization1.11.5
Adjustments to reconcile net income to net cash provided by operating activities:Stock-based compensation17.58.7
Full release

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the Company's expectations regarding future events, financial guidance and financial or operational performance. Forward-looking statements may be identified by words such as "believe," "expect," "intend," "estimate," "plan," "anticipate," "project," "forecast," "guidance," "target," "may," "will," "continue" and similar expressions.

These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. For additional information regarding these risks as well as other risks, uncertainties and factors that could affect our forward-looking statements, please refer to Part I Item 1A, entitled "Risk Factors," of the Company's most recent Annual Report on Form 10-K and any amendments thereto, as well as the Company's most recently filed Quarterly Reports on Form 10-Q and other filings the Company makes with the Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this press release. Except as required by law or regulation, West Pharmaceutical Services, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Non-U.S. GAAP Financial Measures

The Company reports its financial results in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). However, management also uses certain non-U.S. GAAP financial measures in evaluating our results of operations. Management believes that this information provides users with a valuable insight into our overall performance and financial position. As a result, this release contains certain non-GAAP financial measures, including organic net sales, adjusted-diluted EPS and adjusted operating profit. Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign currency exchange rates in effect during the comparable prior-year period. We may also refer to financial results, such as adjusted-diluted EPS and adjusted operating profit, that exclude the effects of unallocated items. The unallocated items are not representative of ongoing operations, and generally include restructuring and related charges, certain asset impairments, and other specifically identified income or expense items. These non-U.S. GAAP financial measures should be viewed in addition to, and not as an alternative for, the Company’s results prepared in accordance with U.S. GAAP. A reconciliation of these non-U.S. GAAP measures to the comparable U.S. GAAP financial measures is included in the accompanying tables.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · West Pharmaceutical Services earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.